Factors affecting outcomes in colonoscopy.
There are many factors that influence successful outcomes in colonoscopy. The aims of this study were to evaluate these factors and determine ways to improve outcomes. All participants (N=229) who underwent planned colonoscopy between July and September 2004 were retrospectively included. Participants included 118 men and 111 women with a mean age of 59 years. Completion rate was 92%. Reasons of failure included poor bowel preparation (2.2%, p< .025), bowel looping (2.2%, p< .025), participant discomfort (1.3%), and obstructing lesion (1.3%). Mean midazolam dose was 3.8 mg. Three participants (1.3%) had midazolam alone, and all had complete colonoscopy. One hundred thirty-three participants (60.7%) had additional meperidine, with a completion rate of 94%. Eighty three participants (37.9%) had additional meperidine and Buscopan, with a completion rate reduced to 89.2%. There was no correlation between sedatives used and completion rate. Completion rate of colonoscopy in our unit was acceptable at 92%. A combination of midazolam and meperidine gave the best completion rates (94%). The two main reasons for incompletion were poor bowel preparation and excessive bowel looping.
Selehi
Seema
S
West Midlands, University Hospitals Coventry, Department of Surgery, Walsgrave, United Kingdom.
Leung
Edmund
E
Wong
Ling
L
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use; D002086:Butylscopolammonium Bromide / Q000009:adverse effects / Q000627:therapeutic use; D002951:Citrates; D003113:Colonoscopy / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D016292:Procedural Sedation / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D054368:Laxatives / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008485:Medical Audit; D008614:Meperidine / Q000009:adverse effects / Q000627:therapeutic use; D008874:Midazolam / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D009942:Organometallic Compounds; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010847:Picolines / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012676:Senna Extract / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D006113:United Kingdom
D000701:Analgesics, Opioid; D002951:Citrates; D006993:Hypnotics and Sedatives; D054368:Laxatives; D018727:Muscarinic Antagonists; D009942:Organometallic Compounds; D010847:Picolines; D002086:Butylscopolammonium Bromide; D012676:Senna Extract; D008614:Meperidine; C005701:picosulfate sodium; D008874:Midazolam